Death but one unintended consequence of gene-therapy trial

Sibbald, Barbara
May 2001
CMAJ: Canadian Medical Association Journal;5/29/2001, Vol. 164 Issue 11, p1612
Academic Journal
Reports on the death of Jesse Gelsinger after participating in a gene-therapy trial at the University of Pennsylvania. His severe immune reaction to a recombinant adenoviral vector used in the study which caused his death; How the case has raised the issue of informed consent, since Jesse was not told of several other patients who experienced serious side effects; Decision of the United States Food and Drug Administration to halt all gene therapy trials at the school and conduct an investigation.


Related Articles

  • A promising experiment ends in tragedy. Roberts, Leslie // U.S. News & World Report;10/11/99, Vol. 127 Issue 14, p43 

    Offers information on the death of Jesse Gelsinger, a participant in a gene-therapy study at the University of Pennsylvania. History of his suffering from ornithene transcarbamylase deficiency (OTC); Goal of the clinical trial to deliver a normal version of a defective gene; Investigation...

  • Humility at the frontier. Cannon, Angie // U.S. News & World Report;12/20/99, Vol. 127 Issue 24, p60 

    Discusses the reaction of United States medical researchers to the death of Jesse Gelsinger, which was caused by gene therapy experimentation. The Recombinant DNA Advisory Committee meeting; Jesse's liver disorder; Questions of wrongdoing in the experiment; The need for stricter rules in...

  • The Real Heroes.  // Review of Ophthalmology;Sep2000, Vol. 7 Issue 9, p22 

    Focuses on the death of Jesse Gelsinger after volunteering for gene therapy. Experiences of Peter Choyce on intraocular lens implantation; Risks and benefits of new treatments.

  • A death in Philadelphia. Hall // Technology Review;Jan/Feb2000, Vol. 103 Issue 1, p87 

    Reports on the death of Jesse Gelsinger during a gene therapy trial. Experimental treatment received for ornithine transcarbamylase deficiency; Problems with gene therapy.

  • Gene Therapy Death - "Everyone Has to Share in the Guilt". Jenks, Susan // JNCI: Journal of the National Cancer Institute;01/19/2000, Vol. 92 Issue 2, p98 

    Focuses on the unexpected gene therapy death of patient Jesse Gelsinger in the United States. Controversy concerning the gene therapy death; Investigation on the issue; Response from several medical experts and physicians.

  • Gene-Therapy Death Likely Due To Age, Weak Immunity. Osborne, Randall // BioWorld Today;7/30/2007, Vol. 18 Issue 146, p1 

    The article focuses on the issues surrounding the death of Jesse Gelsinger, an 18-year old patient included in the clinical trial of a gene therapy for ornithine transcarbamylase deficiency. According to analyst Stephen Dunn, the physician who injected the gene therapy to Gelsinger should have...

  • Congress gets tough with gene therapy. Smaglik, Paul // Nature;2/10/2000, Vol. 403 Issue 6770, p583 

    Focuses on Representative Dennis Kucinich's introduction of a legislation aimed at tightening up the supervision of federally funded human gene-therapy trials in the United States. Response to the death of Arizona resident Jesse Gelsinger; Senate subcommittee's exploration of other issues...

  • Harm, ethics committees and the gene therapy death. Savulescu, Julian // Journal of Medical Ethics;Jun2001, Vol. 27 Issue 3, p148 

    Editorial. Addresses ethical issues regarding gene therapy trials, in reference to the death of Jesse Gelsinger. Background on the case; Goals of ethical reviews of research; Use of the quality adjusted life year approach in conducting trials.

  • A Gene Therapy Death. Silberner, Joanne // Hastings Center Report;Mar/Apr2000, Vol. 30 Issue 2, p6 

    Focuses on the death of 18-year-old Jesse Gelsinger after receiving gene therapy for a rare metabolic disorder. Information on ornithine transcarbamylase deficiency; Series of ethnically questionable features of the protocol unveiled in connection to the death of Gelsinger; Plans to require...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics